Partnerships, Licensing, Investments and M&A Deals and Trends for November 2013 in Pharmaceuticals, New Report Launched

'Partnerships, Licensing, Investments and M&A Deals and Trends for November 2013 in Pharmaceuticals' report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in November 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from Publisher’s proprietary in-house deals database and primary and secondary research.

Scope

• Analysis of the market trends for the pharmaceutical industry in the global arena.
• Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
• Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
• Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
• Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
• Analysis of partnership and licensing deals based on clinical stage of development of products.
• Summary of the pharmaceutical deals globally in the six months.
• Information on the top deals happened in the pharmaceutical industry.
• Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
• League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

• Enhance your decision making capability in a more rapid and time sensitive manner.
• Find out the major deal performing segments for investments in your industry.
• Evaluate the types of company divesting and acquiring assets and ways to raise capital in the market.
• Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the oil and gas industry.
• Identify growth segments and opportunities in each region within the industry.
• Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Spanning over 110 pages, 44 Tables and 39 Figures, “Partnerships, Licensing, Investments and M&A Deals and Trends for November 2013 in Pharmaceuticals” report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in November 2013.

In addition to covering Pharmaceuticals & Healthcare, Global, Deal Summary, Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type, Pharmaceuticals & Healthcare, Global, Partnership Deals, November 2013, Pharmaceuticals & Healthcare, Global, Licensing Agreements, November, Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area, Deal Summary by Geography, Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Further Information.

Inquiry for more information visit: : http://www.marketresearchreports.com/globaldata/partnerships-licensing-investments-and-ma-deals-and-trends-november-2013-pharmaceuticals

Find All Pharma and Healthcare Reports at : http://www.marketresearchreports.com/pharma-healthcare

MediPoint: Knee Replacement - South American Analysis and Market Forecasts, New Report Launched

The current knee replacement market is a crowded space, with an increasing number of companies offering a myriad of partial, primary/total, and revision prostheses to meet orthopedic surgeons’ demands in the management of knee diseases, primarily osteoarthritis. Worldwide, the primary/total knee segment represents about 80–90% of the entire knee market, with the remainder being partial knee and revision knee. Overall, clinical data show that short- to medium-term survivorship is excellent after almost all common types of knee replacement, regardless of fixation, constraint, and bearing type. Future competition among vendors will be more likely to center on the instrumentation and the ancillary equipment, such as patient-specific instruments, navigation systems, and robotic systems.

Brazil’s economy is booming on the back of a growing middle class and rising investment in the physical infrastructure. The medical devices market in Brazil is the largest in South America. In the past few years, a general easing of the import bureaucracy and the requirement to improve the quality and quantity of healthcare services available in Brazil have led to increased adoption of advanced medical technologies, such as total shoulder replacement implants.

Scope

• An overview of hypertension, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized South America Knee replacement market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
• Investigation of current and future market competition for Knee replacement
• Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
• Competitor assessment including device approval analysis and device sales forecasts.
• Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
• Analysis of unmet needs within the market and opportunities for future players.
• Technology trends evaluation to assess strength of pipeline.
• An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
• Company profiles including business description, financial overview and SWOT analysis.
• Coverage of key market players.
• Strategic assessment of the Knee replacement sector through market impact analysis, future market scenario and company analysis.
• Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists

Reasons to buy

• Understand the trends shaping and driving South America Knee replacement market.
• Realize device preferences of physicians who have performed the tests already.
• Access market sizing, forecasts and quantified growth opportunities in South America Knee replacement market through 2018.
• Quantify candidate patient populations to better design product pricing & launch plans.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
• Perform benchmarking analysis of growth opportunities against currently marketed products.
• Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
• Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
• Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
• What’s the next big thing in South America Knee replacement market landscape? Identify, understand and capitalize.

Spanning over 228 pages, 123 Tables and 38 Figures, “MediPoint: Knee Replacement - South American Analysis and Market Forecasts” report covering Disease Overview, Industry Overview, Competitive Assessment, Unmet Needs, Pipeline Products, Current and Future Players, Market Outlooks, Appendix. The report covering 9 companies- B. Braun, Biomet, DePuy Synthes, DJO Surgical, Exactech, Smith & Nephew, Stryker, Wright Medical (MicroPort), Zimmer.

Inquiry for more information visit: : http://www.marketresearchreports.com/globaldata/medipoint-knee-replacement-south-american-analysis-and-market-forecasts

Find All Pharma and Healthcare Reports at : http://www.marketresearchreports.com/pharma-healthcare

MediPoint: Knee Replacement - EU Analysis and Market Forecasts, New Report Launched

The current knee replacement market is a crowded space, with an increasing number of companies offering a myriad of partial, primary/total, and revision prostheses to meet orthopedic surgeons’ demands in the management of knee diseases, primarily osteoarthritis. Worldwide, the primary/total knee segment represents about 80–90% of the entire knee market, with the remainder being partial knee and revision knee. Overall, clinical data show that short- to medium-term survivorship is excellent after almost all common types of knee replacement, regardless of fixation, constraint, and bearing type. Future competition among vendors will be more likely to center on the instrumentation and the ancillary equipment, such as patient-specific instruments, navigation systems, and robotic systems.

Similarly, on the opposite side of the Atlantic, the expanding patient population for orthopedic surgical treatments, the widespread appreciation of the clinical efficacy of knee replacement, and the steady domestic supply of orthopedic devices in the European countries have all contributed to a stable increase in the procedure volume in the past decades. However, the recent European sovereign debt crisis is putting pressure on the 5EU countries (France, Germany, Italy, Spain, and UK) to put measures in place to prevent excessive healthcare budget deficits.

Scope

• An overview of hypertension, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized EU Knee replacement market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
• Investigation of current and future market competition for Knee replacement
• Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
• Competitor assessment including device approval analysis and device sales forecasts.
• Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
• Analysis of unmet needs within the market and opportunities for future players.
• Technology trends evaluation to assess strength of pipeline.
• An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
• Company profiles including business description, financial overview and SWOT analysis.
• Coverage of key market players.
• Strategic assessment of the Knee replacement sector through market impact analysis, future market scenario and company analysis.
• Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists

Reasons to buy

• Understand the trends shaping and driving EU Knee replacement market.
• Realize device preferences of physicians who have performed the tests already.
• Access market sizing, forecasts and quantified growth opportunities in EU Knee replacement market through 2018.
• Quantify candidate patient populations to better design product pricing & launch plans.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
• Perform benchmarking analysis of growth opportunities against currently marketed products.
• Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
• Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
• Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
• What’s the next big thing in EU Knee replacement market landscape? Identify, understand and capitalize.

Spanning over 257 pages, 131 Tables and 52 Figures, “MediPoint: Knee Replacement - EU Analysis and Market Forecasts” report covering Disease Overview, Industry Overview, Competitive Assessment, Unmet Needs, Pipeline Products, Current and Future Players, Market Outlooks, Appendix. The report covering 9 companies- B. Braun, Biomet, DePuy Synthes, DJO Surgical, Exactech, Smith & Nephew, Stryker, Wright Medical (MicroPort), Zimmer.

Inquiry for more information visit: : http://www.marketresearchreports.com/globaldata/medipoint-knee-replacement-eu-analysis-and-market-forecasts

Find All Pharma and Healthcare Reports at : http://www.marketresearchreports.com/pharma-healthcare

MediPoint: Knee Replacement - APAC Analysis and Market Forecasts, New Report Launched

The current knee replacement market is a crowded space, with an increasing number of companies offering a myriad of partial, primary/total, and revision prostheses to meet orthopedic surgeons’ demands in the management of knee diseases, primarily osteoarthritis. Worldwide, the primary/total knee segment represents about 80–90% of the entire knee market, with the remainder being partial knee and revision knee. Overall, clinical data show that short- to medium-term survivorship is excellent after almost all common types of knee replacement, regardless of fixation, constraint, and bearing type. Future competition among vendors will be more likely to center on the instrumentation and the ancillary equipment, such as patient-specific instruments, navigation systems, and robotic systems.

In contrast to the general picture in developed countries, the APAC countries are relative laggards in the utilization of knee replacement, primarily due to the slow rate of adoption of a westernized lifestyle and OA development in their populations. Japan is comparable to the 5EU and US from the perspective of product adoption and the utilization of healthcare services, yet the knee replacement procedure volume in Japan is expected to increase at a slower pace than in India and China.

Scope

• An overview of hypertension, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized APAC Knee replacement market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
• Investigation of current and future market competition for Knee replacement
• Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
• Competitor assessment including device approval analysis and device sales forecasts.
• Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
• Analysis of unmet needs within the market and opportunities for future players.
• Technology trends evaluation to assess strength of pipeline.
• An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
• Company profiles including business description, financial overview and SWOT analysis.
• Coverage of key market players.
• Strategic assessment of the Knee replacement sector through market impact analysis, future market scenario and company analysis.
• Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists

Reasons to buy

• Understand the trends shaping and driving APAC Knee replacement market.
• Realize device preferences of physicians who have performed the tests already.
• Access market sizing, forecasts and quantified growth opportunities in APAC Knee replacement market through 2018.
• Quantify candidate patient populations to better design product pricing & launch plans.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
• Perform benchmarking analysis of growth opportunities against currently marketed products.
• Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
• Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
• Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
• What’s the next big thing in APAC Knee replacement market landscape? Identify, understand and capitalize.

Spanning over 245 pages, 125 Tables and 42 Figures, “MediPoint: Knee Replacement - APAC Analysis and Market Forecasts” report covering Disease Overview, Industry Overview, Competitive Assessment, Unmet Needs, Pipeline Products, Current and Future Players, Market Outlooks, Appendix. The report covering 9 companies- B. Braun, Biomet, DePuy Synthes, DJO Surgical, Exactech, Smith & Nephew, Stryker, Wright Medical (MicroPort), Zimmer.

Inquiry for more information visit: : http://www.marketresearchreports.com/globaldata/medipoint-knee-replacement-apac-analysis-and-market-forecasts

Find All Pharma and Healthcare Reports at : http://www.marketresearchreports.com/pharma-healthcare

MediPoint: Knee Replacement - Current and Future Players, New Report Launched

The current knee replacement market is a crowded space, with an increasing number of companies offering a myriad of partial, primary/total, and revision prostheses to meet orthopedic surgeons’ demands in the management of knee diseases, primarily osteoarthritis. Worldwide, the primary/total knee segment represents about 80–90% of the entire knee market, with the remainder being partial knee and revision knee. Overall, clinical data show that short- to medium-term survivorship is excellent after almost all common types of knee replacement, regardless of fixation, constraint, and bearing type. Future competition among vendors will be more likely to center on the instrumentation and the ancillary equipment, such as patient-specific instruments, navigation systems, and robotic systems.

The report identifies and analyzes the key companies shaping and driving the global knee replacement market. The report provides insight into the competitive knee replacement landscape, including new companies entering the market and pipeline products in development. This report is built using data and information sourced from proprietary databases, secondary sources and primary research interviews and survey with leading cardiologists, with in-house analysis conducted by GlobalData’s team of industry experts.

Scope

• Investigation of current and future market competition for knee replacement
• Competitor assessment including device approval analysis.
• Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
• Strategic assessment of the device sector through market impact analysis, future market scenario and company analysis.
• Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists using knee replacement devices in clinical practice.

Reasons to buy

• Gain a high level view of the trends shaping and driving the knee replacement market for coronary applications and peripheral applications in the lower extremity.
• Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape
• Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
• Create an effective counter-strategy to gain a competitive advantage against those currently in the market

Spanning over 152 pages, 116 Tables and 21 Figures, “MediPoint: Knee Replacement - Current and Future Players” report covering Related Reports, Competitive Assessment, Pipeline Products, Current and Future Players, Appendix. The report covering 9 companies- B. Braun, Biomet, DePuy Synthes, DJO Surgical, Exactech, Smith & Nephew, Stryker, Wright Medical (MicroPort), Zimmer.

Inquiry for more information visit: : http://www.marketresearchreports.com/globaldata/medipoint-knee-replacement-current-and-future-players

Find All Pharma and Healthcare Reports at : http://www.marketresearchreports.com/pharma-healthcare

EpiCast Report: Ulcerative Colitis - Epidemiology Forecast to 2022, New Report Launched

Ulcerative colitis is a chronic inflammatory bowel disease (IBD) that causes ulcers in the innermost lining of the colon and rectum. The colon’s ability to absorb water is decreased, which leads to progressive loosening of the stool, bloody stool, and sometimes cramping or abdominal pain with urgency for bowel movement (CDC, 2013; NDDIC, 2013). The exact cause or triggers of the disease are yet to be identified. Globally, the incidence of ulcerative colitis varied from 0.34 cases per 100,000 population in China to as high as 15.1 cases per 100,000 population in the UK in the 1990s (Lok et al., 2008; Shivananda et al., 1996). The diagnosed prevalence of the condition ranged between 6.3 cases per 100,000 population in China in 2006 and 243 cases per 100,000 population in the UK during 2000–2002 (Lok et al., 2008; Rubin et al., 2000).

Epidemiologists forecast that there were 134,109 incident cases of ulcerative colitis in the 10MM in 2012, and the number of incident cases will grow 12.2% over the next decade to 150,530 incident cases. In 2012, there were 1,860,616 prevalent cases of ulcerative colitis in the 10MM. Each of the 10MM, except Germany, will see an increase in prevalent cases over the 10-year forecast period.

This forecast is supported by historical data for ulcerative colitis gathered from peer-reviewed journals and country-specific studies, in addition to reports taken from national health authorities and international organizations with interests in gastroenterology or inflammatory bowel disease (IBD). Another major strength of this analysis is that to take into account historical trends of ulcerative colitis and provide a robust forecast, epidemiologists conducted linear regression analysis whenever sufficient historical data were available and the literature supported the resulting trend.

Scope

• The ulcerative colitis EpiCast Report provides an overview of the risk factors and global trends of ulcerative colitis in the 10MM (US, France, Germany, Italy, Spain, UK, Japan, Canada, China, and India). It includes a 10-year epidemiological forecast for the incident cases of ulcerative colitis segmented by sex and age (in five-year age groups beginning at 10 years and ending at 85 years and older), in addition to prevalent cases in these markets.
• The ulcerative colitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

• Develop business strategies by understanding the trends shaping and driving the global ulcerative colitis market.
• Quantify patient populations in the global ulcerative colitis market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for ulcerative colitis therapeutics in each of the markets covered.

Spanning over 73 pages, 12 Tables and 11 Figures, “EpiCast Report: Ulcerative Colitis - Epidemiology Forecast to 2022” report covering Introduction, Epidemiology, Appendix.

Inquiry for more information visit: : http://www.marketresearchreports.com/globaldata/epicast-report-ulcerative-colitis-epidemiology-forecast-2022

Find All Pharma and Healthcare Reports at : http://www.marketresearchreports.com/pharma-healthcare

The Global Parkinson’s Disease (PD) Market is Expected to Decline From $3.4 Billion in 2012 to $2.9 Billion By 2019

Due to upcoming patent expirations for four high-profile drugs, the global Parkinson’s Disease (PD) market is expected to decline from $3.4 billion in 2012 to $2.9 billion by 2019, at a negative Compound Annual Growth Rate (CAGR) of 2.3%.

The latest report states that PD drugs, such as Azilect (rasagiline mesylate), Stalevo (levodopa, carbidopa, entacapone) and Comtan (entacapone), will lose their patents by the end of the forecast period. Generic alternatives for these treatments have already been approved, which will result in further market competition.

Additionally, the loss of patent for Mirapex (pramipexole dihydrochloride) and Exelon (rivastigmine tartrate) in 2010 and 2012 will continue to halt future PD market growth.

Analyst of this report says: “In the most likely scenario, late-stage pipeline drugs, including Rytary, safinamide and pimavanserin, are expected to be approved and launched in the market within the forecast period. However, this won’t be significant enough to diminish the impact of generic erosion.”

Furthermore, with the majority of existing PD drugs focusing on symptomatic relief, a disease-modifying treatment remains an urgent unmet need in the PD market. The current pipeline consists of 21% neuroprotective targets, while 87% are currently in discovery and preclinical development. The remaining molecules are distributed in Phase I and Phase II.

“These targets represent innovation in the pipeline and could become effective disease-modifying treatments in the future. However, the development of such medication faces several challenges, including the absence of neuroprotective candidates in the late pipeline and the need for a reliable biomarker that can accelerate such development,” the analyst concludes.

This report provides in-depth analysis of the drugs available for the treatment of Parkinson’s Disease, covering their safety, efficacy, treatment patterns, and strengths/weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy. It gives multi-scenario market forecast data to 2019, taking into account the introduction of new drugs, the expiration of key patents, and changes in disease epidemiology across the US, Canada, France, Germany, Italy, Spain, the UK and Japan.

For more information please visit: http://www.marketresearchreports.com/gbi-research/parkinsons-disease-therapeutics-market-2019-pipeline-shows-shift-towards-long-term

Browse other market research reports in diseases at http://www.marketresearchreports.com/diseases

The market value for monoclonal antibodies (mAbs) in colorectal cancer treatment is expected to reach $5.2 billion by 2019

The market value for monoclonal antibodies (mAbs) in colorectal cancer treatment will experience a moderate increase from $3.7 billion in 2012 to $5.2 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 5%.

The company’s report states that this moderate growth is due to the slow rise of the prevalent population and weakness of the late-stage pipeline. Currently, there is only one mAb product in Phase III development for the treatment of colorectal cancer, named IMC-1121B.

Analyst of this report says: “The efficacy of this drug has not yet been proven in large-scale, placebo-controlled 

Phase III trials, which creates an element of uncertainty in terms of the outcome of these products. As such, this weak late-stage pipeline is not expected to drive market growth to a significant extent during the forecast period.”

The current metastatic colorectal cancer market is dominated by three mAbs— Avastin, Erbitux and Vectibix — which are far more efficacious than the targeted small molecule therapies also marketed for this setting. Therefore, GBI Research believes there is a strong opportunity for the entry of new mAbs into the market, as long as they prove superior efficacy when compared to Avastin.

Analyst says: “A product that can attain first-line status in the treatment of colorectal cancer, or even second-line status by displacing Erbitux and Vectibix, would have access to a considerable patient population and be able to generate a substantial amount of revenue.

“Furthermore, there are currently no approved mAbs in the early-stage setting for colorectal cancer, reflecting an additional opportunity for the development of new products,” the analyst concludes.

This report provides in-depth analysis of three mAbs marketed for colorectal cancer, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. It also gives a comprehensive review of the pipeline for colorectal cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period.

For more information please visit: http://www.marketresearchreports.com/gbi-research/monoclonal-antibodies-market-colorectal-cancer-2019-favorable-pricing-policy-us-and

Browse other market research reports in diseases at http://www.marketresearchreports.com/diseases

Cardiovascular Disease (CVD) market is expected to reach $18.2 billion by 2019

The global market for Cardiovascular Disease (CVD) — comprised of Heart Failure (HF), Myocardial Infarction and Acute Coronary Syndrome (ACS) — is expected to grow at a moderate rate, from $13.7 billion in 2012 to $18.2 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 4.1%.

The latest report states that out of the eight major markets (the US, France, Germany, Italy, Spain, UK, Japan and Canada), the US will boast the largest value, from $6.1 billion in 2012 to $8.49 billion by 2019, at a higher CAGR of 4.7%.

This growth is partially due to the increase of the treatment population, which is forecast to jump from 14 million in 2012 to 16 million by 2019, at a CAGR of 1.6%.New drugs are also expected to have a positive impact upon the CVD market, including LCZ696 and Serelaxin by Novartis, AZD6140 by AstraZeneca and BAY81-8781 by Bayer.

Analyst of this report, says: “Over recent decades, a large amount of research and innovation has been incorporated in the cardiovascular therapeutics market segment. Of the whole pipeline, 37% of drugs are undergoing Phase II and Phase III trials. This indicates a strong pipeline capable of boosting the market in the coming years.”

However, the CVD market is hampered by high costs, with the annual cost of treatment for the three CVD indications estimated to increase from $4,214 in 2012 to $4,876 by 2019, at a CAGR of 2.1%.

“New therapy drugs, such as LCZ696 and Serelaxin by Novartis, are promising upcoming treatments that will be expensive due to their specificity. This will in turn consume a large share of patients’ healthcare expenditure, which is somewhat unavoidable,” the analyst concludes.

This report provides an in-depth analysis of the cardiovascular therapeutic indications, namely heart failure, myocardial infarction (MI), and acute coronary syndrome (ACS) in the eight major markets — the US, France, Germany, Italy, Spain, UK, Japan and Canada. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three cardiovascular indications.

For more information please visit: http://www.marketresearchreports.com/gbi-research/cardiovascular-diseases-therapeutics-major-developed-markets-2019-increasing-prevalence

Browse other market research reports in diseases at http://www.marketresearchreports.com/diseases

The Ophthalmology Therapeutics Market For Dry Eye Syndrome (DES) is Expected To Reach $6.1 Billion By 2019

 

The ophthalmology therapeutics market for Dry Eye Syndrome (DES) and glaucoma in the eight major countries — the US, the UK, France, Germany, Italy, Spain, Canada and Japan — is expected to increase moderately, climbing from $3.7 billion in 2012 to $6.1 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 7.6%.

According to the latest report, the five European countries are expected to show the fastest growth over the forecast period, with a CAGR of 20.4%. Meanwhile, the three remaining markets will witness slightly lower CAGRs, with Canada at 9.8%, the US at 4.3% and Japan at 2.7%.

A major factor driving the market expansion is the fact that the ophthalmology pipeline is becoming increasingly innovative, with a number of promising drugs in late-stage development and a cluster of novel molecules in the early stages.

Analyst of this report, says: “There are currently five molecules in the pre-registration stage that are expected to be granted approval within the forecast period. Two of these are indicated for DES and three for glaucoma. Additionally, nearly 36% of the pipeline for glaucoma and DES consists of molecules already in the late stages of development.”

Other market drivers include the rising awareness of the importance of detecting ophthalmic diseases early, the availability of effective diagnostic tools and an increase in the prevalence of both DES and glaucoma.

However, the ophthalmology market will face major barriers during the forecast period, including the loss of patent for many blockbuster drugs, such as Lumigan, which will lead to subsequent pressure from cheaper off-label products.

“Governments will always favor low-cost generics and encourage pharmaceutical firms to keep drug prices low. In many cases, governments substantially control patient access to medications, making it difficult for branded manufacturers to recover the research and development costs involved in drug discovery,” the analyst concludes.

This report provides in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these two ophthalmology indications.

For more information please visit: http://www.marketresearchreports.com/gbi-research/ophthalmology-therapeutics-major-developed-markets-2019-new-drug-approvals-and

Browse other market research reports in diseases at http://www.marketresearchreports.com/diseases

Global Procedures for Fractures and Degenerative Disc Disease, New Report Launched

This report pertains to a forecast period of 10 years (2009 – 2019) for North America, including Canada and the United States; Oceania, including Australia and New Zealand; Latin America, including Argentina, Mexico, Brazil and Other Countries; Europe, including Germany, Frange, the U.K., Italy, Spain, Belgium, the Netherlands, Denmark, Finland, Norway, Sweden, Austria, Switzerland and Portugal.  Inquire about this report: http://www.marketresearchreports.com/idata-research/global-procedures-fractures-and-degenerative-disc-disease

Reasons To Buy -

1. This report analyzes and evaluates the current state of the market including existing and potential markets, product average selling prices, and unit volumes. The report also highlights the opportunities and potential hazards involved, and presents strategies for successfully navigating the market landscape.

2. Furthermore, it seeks to identify the trends and technologies that will affect the future of each market segment and prepares an unbiased critical assessment of such market drivers and limiters based on a 'ground up' approach, which includes primary and secondary research methods.

Report Contents-

• Market Forecast and Analysis
• Identify Strategic Opportunities
• Final Review and Market Release
• Customer Feedback and Market Monitoring

Main Segments Included-

• Fractures
• Degenerative Disc Disease
• Avascular Necrosis

Spanning over 180 pages,“Global Procedures for Fractures and Degenerative Disc Disease” report covering the Incidence Of Fractures, Soft Tissue Damage, North America, Oceania, Latin America, Europe; Degenerative Disc Disease - United States, Australia , Latin America; Avascular Necrosis; Appendix: Statistics; Abbreviations. The report cover 6 companies - Ameridose, Baxa Corporation/Baxter International, Health Care Logistics, International Medical Industries, Medi-Dose/EPS/Vu-Pak, PharMEDium/B. Braun.

Find all Pharmaceuticals and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Latin American Minimally Invasive Surgery Spinal Implant Market is Expected To Reach $60.7 Million by 2019, Revels New Report

The Latin American minimally invasive surgery spinal implant market includes minimally invasive interbody fusion and minimally invasive pedicle screws. Growth is expected in both segments as a result of the physiological and surgical advantages of MIS procedures. MIS interbody fusion was the most rapidly growing segment in 2012, followed by MIS pedicle screws.

This report pertains to a forecast period of 10 years (2009 – 2019) for Argentina, Brazil and Mexico.

Inquire about this report: http://www.marketresearchreports.com/idata-research/latin-american-markets-minimally-invasive-spinal-implants

Reasons To Buy:-

1. This report analyzes and evaluates the current state of the market including existing and potential markets, product average selling prices, and unit volumes. The report also highlights the opportunities and potential hazards involved, and presents strategies for successfully navigating the market landscape.

2. Furthermore, it seeks to identify the trends and technologies that will affect the future of each market segment and prepares an unbiased critical assessment of such market drivers and limiters based on our “ground up” approach, which includes primary and secondary research methods.

Report Contents: -

• Competitor Analysis
• Identified Strategic Opportunities
• Market Overview by Segment & Country
• Trend Analysis by Segment & Country
• Market Drivers & Limiters
• Mergers & Acquisitions
• Customer Feedback and Market Monitoring

Main Segments Included:-

• MIS Interbody Fusion Market
• MIS Pedicle Screw Market
• Emerging Technologies

Sub-Segments Included: -

• Minimally Invasive Posterior Lumbar Interbody Fusion
• Minimally Invasive Transforaminal Lumbar Interbody Fusion
• Lateral Lumbar Interbody Fusion
• Direct Lateral Interbody Fusion (DLIF®)
• eXtreme Lateral Interbody Fusion (XLIF®)
• Guided Lateral Interbody Fusion (GLIF™)
• Other Lateral Interbody Devices and Systems
• Retractor MIS Pedicle Screw Market
• Percutaneous MIS Pedicle Screw Market
• Spinous Process Fixation
• Facet Fixation
• Minimally Invasive Sacroiliac Joint Fusion

Spanning over 164 pages, “Latin American Markets for Minimally Invasive Spinal Implants” report covering Executive Summary, Research Methodology, Latin American Minimally Invasive Surgery (MIS) Spinal Implant Market, The Human Spine, Country Profiles, MIS Interbody Fusion Market, MIS Pedicle Screw Market, Emerging Technologies. The report cover 12 companies - Aesculap, Alphatec Spine, DePuy Synthes, Globus, K2M, LDR, Medical, Medtronic, NuVasive, Orthofix, Stryker, Zimmer.

Find all Pharmaceuticals and Healthcare Reports at:

http://www.marketresearchreports.com/pharma-healthcare

U.S. and South Korean Markets for Medical Video Recorders (2 Reports), New Report Launched

In the U.S., medical-grade image capture/video recording devices are significantly more expensive than equivalent hardware used in other applications because of the regulatory certification process that the devices are subject to. The market for these devices suffered in 2009 because of the effects of the U.S. recession; during this period, many hospitals and purchasing institutions delayed capital equipment purchases. However, stable growth of this market will be supported by the continued need for data acquisition as the U.S. healthcare system becomes increasingly data driven.

In the South Korean market for medical-grade image capture and recording devices, the number of units sold is expected to increase over the 2011–2017 forecast period. In South Korea, medical video recorders are significantly more expensive than equivalent hardware used in other applications because of the regulatory certification process that the devices are subject to. The market for these devices suffered in 2009 because of the effects of the economic recession; during this period, many hospitals and purchasing institutions delayed capital equipment purchases. However, stable growth of this market over the forecast period will be supported by the continued need for data acquisition, as the South Korean healthcare system becomes increasingly data driven.

This report pertains to a forecast period of 10 years (2007 – 2017) for the U.S. and South Korea.

Reasons To Buy

1. This report analyzes and evaluates the current state of the market including existing and potential markets, product average selling prices, and unit volumes. The report also highlights the opportunities and potential hazards involved, and presents strategies for successfully navigating the market landscape.

2. Furthermore, it seeks to identify the trends and technologies that will affect the future of each market segment and prepares an unbiased critical assessment of such market drivers and limiters based on our “ground up” approach, which includes primary and secondary research methods.

Report Contents -

• Competitor Analysis and Distribution Channels
• Identified Strategic Opportunities
• Market Overview by Segment & Country
• Trend Analysis by Segment & Country
• Market Drivers & Limiters
• Mergers & Acquisitions
• Customer Feedback and Market Monitoring

Main Segments Included-

• Market Penetration by Setting
• PACS Penetration by Hospital Type
• Medical Video Recorders Use by Specialty
• HD Medical Video Recorder Market
• SD Medical Video Recorder Market
• Market by Single Product versus System
• Market Penetration by Specialty

Inquire about this report: http://www.marketresearchreports.com/idata-research/us-and-south-korean-markets-medical-video-recorders-2-reports

Find all Medical Devices Reports at: http://www.marketresearchreports.com/medical-devices